Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries, New Report Launched

The global market for Major Depressive Disorder (MDD) therapeutics was valued at $8.7 billion in 2013, and several key patent expiries will cause it to decline at a negative Compound Annual Growth Rate (CAGR) of 4% to $7.4 billion by 2017.

The "Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries" report states that following this decline, new drug launches after 2017 will reinvigorate the market, which will increase at a CAGR of 3.5% to $8.1 billion by 2020.

Senior Analyst, explains: “A host of blockbuster drugs, including Abilify and Seroquel XR, which achieved combined sales of more than $6 billion in 2013, are due to expire by 2017. They will be succeeded by the entry of inexpensive generics.

“However, seven new pipeline products are expected to be approved during the forecast period, and Lundbeck/Takeda’s Brintellix, which was launched this year, will lead the market. This is due to the drug’s novel, multimodal mechanism of action and its safety profile, which is comparable to that of a selective serotonin reuptake inhibitor.”

Of the eight major markets (the US, UK, Italy, France, Spain, Germany, Japan and Canada), the US will continue to be the leading contributor to the MDD space, despite a decline at a negative CAGR of 0.7% from just over $6.3 billion in 2013 to $6 billion by 2020.

Senior Analyst comments: “The US has the largest prevalent population with 18.9 million MDD sufferers in 2013, rising to 21.9 million by 2020. Furthermore, this population will grow the fastest in the US during the forecast period, due to lifestyle, environmental and genetic factors.”

Despite this, the analyst notes that the US’ pharmacological treatment rate is only around 29.5% of the prevalent population.

The lack of mental health awareness, and the social stigma associated with such conditions, leads to hesitance in seeking psychiatric help. This will continue to be a major barrier to MDD market growth,” Singh concludes.

Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries report provides analysis of treatment use patterns, market characterization, drug pipelines and key licensing and co-development deals for major depressive disorder in the key developed markets of the US, the UK, France, Germany, Italy, Spain, Japan and Canada.

Spanning over 70 pages, “Major Depressive Disorder Therapeutics in Major Developed Markets to 2020 - New Launches and Modest Uptake of New Adjunctive Treatments to Offset Patent Expiries” report covering the Introduction, Marketed Products, Major Depressive Disorder Market to 2020 – Pipeline Products, Market Forecast to 2020, Deals and Strategic Consolidations, Appendix.

Know more about this report at – http://mrr.cm/Z95

Find all Treatments Report at: http://www.marketresearchreports.com/treatments